Thursday, May 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

Summary

In this episode of the Daily Remedy Podcast, Dr. Jeffrey Singer discusses his book ‘Your Body, Your Health Care,’ emphasizing the importance of patient autonomy in healthcare. He explores historical cases that shaped medical ethics, critiques government regulations that infringe on personal health decisions, and advocates for harm reduction policies. Dr. Singer also delves into the role of the FDA and the implications of Certificate of Need laws, ultimately calling for a reevaluation of how healthcare is governed to prioritize individual rights.

Takeaways

Patient autonomy is a fundamental principle in healthcare.
Historical cases like Schloendorf vs. Society of New York Hospital highlight the importance of consent.
Government regulations often infringe on personal health choices.
Harm reduction strategies are inconsistently applied across different substances.
The FDA’s role in drug approval can delay access to necessary medications.
Certificate of Need laws restrict competition and access to healthcare services.
Doctors have shifted from paternalistic approaches to respecting patient choices.
The government often acts as a gatekeeper in healthcare decisions.
There is a contradiction in how harm reduction is applied to legal vs. illegal substances.
A new Hippocratic oath should prioritize patient autonomy and respect for individual choices.

 

 

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!